马拉维若在 HIV-1 感染经治患者中的 5 年安全性评价。
Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients.
机构信息
*Weill Cornell Medical College, New York, NY; †University Hospital of Cologne, Cologne, Germany; ‡Pfizer, Inc, Groton, CT; §David Geffen School of Medicine at UCLA, Los Angeles, CA; ‖Chelsea and Westminster Hospital, London, United Kingdom; ¶ViiV Healthcare, Research Triangle Park, NC; #Pfizer, Inc, New York, NY; and **Bristol-Myers Squibb, Wallingford, CT. 1Deceased.
出版信息
J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):78-81. doi: 10.1097/QAI.0b013e3182a7a97a.
Abstract
BACKGROUND
Maraviroc is unique among approved antiretroviral drugs in targeting the host-cell chemokine coreceptor type-5 receptor. With its novel mechanism of action, we sought to describe the 5-year safety profile of maraviroc.
METHODS
Two large phase 3 studies of maraviroc enrolled HIV-infected treatment-experienced patients and followed them up for 5 or more years. Survival and selected clinical end points were identified and assessed.
RESULTS
A total of 938 enrolled patients received maraviroc-containing regimens. Rates of death and selected clinical events (eg, hepatic failure, malignancy, and myocardial infarction) were low during follow-up.
CONCLUSIONS
Maraviroc was generally safe in treatment-experienced participants for >5 years.
摘要
背景
马拉维若在已批准的抗逆转录病毒药物中是唯一靶向宿主细胞趋化因子核心受体 5 型受体的药物。由于其新颖的作用机制，我们试图描述马拉维若的 5 年安全性概况。
方法
两项大型马拉维若的 3 期研究招募了已接受治疗的 HIV 感染经验丰富的患者，并对他们进行了 5 年以上的随访。确定并评估了生存率和选定的临床终点。
结果
共有 938 名入组患者接受了含有马拉维若的治疗方案。在随访期间，死亡率和选定的临床事件（如肝衰竭、恶性肿瘤和心肌梗死）发生率较低。
结论
马拉维若在治疗经验丰富的患者中 >5 年的使用总体上是安全的。
相似文献
1
Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients.
J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):78-81. doi: 10.1097/QAI.0b013e3182a7a97a.
2
Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.
J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):558-64. doi: 10.1097/QAI.0b013e3181ee3d82.
3
Clinical utility of maraviroc.
Clin Drug Investig. 2011;31(8):527-542. doi: 10.2165/11590700-000000000-00000.
4
Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.
Drugs. 2010 Jun 18;70(9):1189-213. doi: 10.2165/11203940-000000000-00000.
5
Maraviroc for previously treated patients with R5 HIV-1 infection.
N Engl J Med. 2008 Oct 2;359(14):1429-41. doi: 10.1056/NEJMoa0803152.
6
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
N Engl J Med. 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154.
7
Drug safety evaluation of maraviroc for the treatment of HIV infection.
Expert Opin Drug Saf. 2012 Jan;11(1):161-74. doi: 10.1517/14740338.2012.640670. Epub 2011 Nov 26.
8
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.
J Infect Dis. 2009 Jun 1;199(11):1638-47. doi: 10.1086/598965.
9
Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.
AIDS Res Hum Retroviruses. 2013 Sep;29(9):1203-10. doi: 10.1089/AID.2012.0330. Epub 2013 Jun 25.
10
Developing clinical role of a CCR5 co-receptor antagonist in HIV-1 infection.
Expert Opin Pharmacother. 2008 Dec;9(18):3231-42. doi: 10.1517/14656560802576324.
引用本文的文献
1
Cardiovascular Disease in HIV Patients: A Comprehensive Review of Current Knowledge and Clinical Implications.
Int J Mol Sci. 2025 Feb 21;26(5):1837. doi: 10.3390/ijms26051837.
2
Treatment with the CCR5 antagonist OB-002 reduces lung pathology, but does not prevent disease in a Syrian hamster model of SARS-CoV-2 infection.
PLoS One. 2025 Feb 5;20(2):e0316952. doi: 10.1371/journal.pone.0316952. eCollection 2025.
3
The Phenomenon of Antiretroviral Drug Resistance in the Context of Human Immunodeficiency Virus Treatment: Dynamic and Ever Evolving Subject Matter.
Biomedicines. 2024 Apr 20;12(4):915. doi: 10.3390/biomedicines12040915.
4
Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5.
bioRxiv. 2024 Feb 12:2023.11.15.567150. doi: 10.1101/2023.11.15.567150.
5
CR5/CCL5 axis is linked to a poor outcome, and inhibition reduces metastasis in oral squamous cell carcinoma.
J Cancer Res Clin Oncol. 2023 Dec;149(19):17335-17346. doi: 10.1007/s00432-023-05443-1. Epub 2023 Oct 13.
6
CCR5 drives NK cell-associated airway damage in pulmonary ischemia-reperfusion injury.
JCI Insight. 2023 Nov 8;8(21):e173716. doi: 10.1172/jci.insight.173716.
7
Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease.
PLoS One. 2023 Jul 14;18(7):e0288598. doi: 10.1371/journal.pone.0288598. eCollection 2023.
8
Case series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequelae of COVID (PASC).
Front Med (Lausanne). 2023 Feb 8;10:1122529. doi: 10.3389/fmed.2023.1122529. eCollection 2023.
9
Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305).
AIDS Behav. 2022 Dec;26(12):4107-4114. doi: 10.1007/s10461-022-03736-z. Epub 2022 Jun 10.
10
A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study).
AIDS Res Hum Retroviruses. 2022 Apr;38(4):269-278. doi: 10.1089/AID.2021.0096. Epub 2021 Sep 14.
本文引用的文献
1
Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials.
J Infect. 2012 Oct;65(4):326-35. doi: 10.1016/j.jinf.2012.05.008. Epub 2012 May 24.
2
Hepatic safety and tolerability in the maraviroc clinical development program.
AIDS. 2010 Nov 13;24(17):2743-50. doi: 10.1097/QAD.0b013e32833f9ce2.
3
Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.
J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):558-64. doi: 10.1097/QAI.0b013e3181ee3d82.
4
Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.
J Acquir Immune Defic Syndr. 2010 Aug;54(5):470-6. doi: 10.1097/qai.0b013e3181e2cba0.
5
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.
J Infect Dis. 2010 Feb 1;201(3):318-30. doi: 10.1086/649897.
6
Developing clinical role of a CCR5 co-receptor antagonist in HIV-1 infection.
Expert Opin Pharmacother. 2008 Dec;9(18):3231-42. doi: 10.1517/14656560802576324.
7
Maraviroc for previously treated patients with R5 HIV-1 infection.
N Engl J Med. 2008 Oct 2;359(14):1429-41. doi: 10.1056/NEJMoa0803152.
8
9
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.
Nat Med. 2005 Nov;11(11):1170-2. doi: 10.1038/nm1319. Epub 2005 Oct 5.
Zotero 插件